Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRSP posted a 19% gain in August after second-quarter earnings showed the company's approved gene-editing therapy Casgevy generated $76 million in sales, up 78% quarter-over-quarter. The FDA expanded Casgevy's label to include pediatric patients aged 2 and older during the period, broadening the addressable market for the sickle cell disease and beta thalassemia treatment.

The biotech also reported $10.2 million in total revenue for the quarter, boosted by a $10 million upfront licensing payment. Net losses narrowed compared to the prior-year period, though specific loss figures were not disclosed in the August update.

The Casgevy sales trajectory marks a critical inflection point for CRSP, which shares commercial rights with partner VRTX. The quarterly revenue jump suggests initial patient uptake is accelerating following the therapy's approval earlier this year. The pediatric label expansion opens access to younger patients who can now receive treatment before complications from chronic transfusions accumulate.